| Pharmacology of stone disease. | |
| | |
MedLine Citation:
|
PMID: 19095203 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs. |
| | |
Authors:
|
Khashayar Sakhaee |
Related Documents
:
|
18156813 - Molecular basis of autosomal recessive polycystic kidney disease (arpkd). 15930963 - Kidney insufficiency and nutrient-based modulation of inflammation. 21977083 - Wilson's disease: mri features. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Advances in chronic kidney disease Volume: 16 ISSN: 1548-5609 ISO Abbreviation: Adv Chronic Kidney Dis Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2008-12-19 Completed Date: 2009-02-02 Revised Date: 2011-07-28 |
Medline Journal Info:
|
Nlm Unique ID: 101209214 Medline TA: Adv Chronic Kidney Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 30-8 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8885, USA. Khashayar.sakhaee@utsouthwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alkalies
/
therapeutic use* Allopurinol / therapeutic use* Animals Drug Design Enzyme Inhibitors / therapeutic use Humans Nephrolithiasis / drug therapy* Sodium Chloride Symporter Inhibitors / therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
M01 RR000633-30/RR/NCRR NIH HHS; M01-RR00633/RR/NCRR NIH HHS; P01 DK020543-23/DK/NIDDK NIH HHS; P01-DK20543/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Alkalies; 0/Enzyme Inhibitors; 0/Sodium Chloride Symporter Inhibitors; 315-30-0/Allopurinol |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prospects for dietary therapy of recurrent nephrolithiasis.
Next Document: Imaging in diagnosis, treatment, and follow-up of stone patients.